Fig. 2

Wnt/β-catenin signaling activation is more beneficial than pathway antagonism in the acute bleomycin model (A) Study design, indicating 21-day duration and biweekly dosing starting on day 7 after intratracheal bleomycin administration. (B) Schematic representing the test molecules and their receptor interaction: R2M3 only binds and antagonizes FZD receptors, inhibiting the pathway, and the tetravalent, bispecific R2M3-26 WNT mimetic binds FZDs and LRPs and activates the pathway. (C) Percentage bodyweight relative to the day 0 value over time. The legend for the treatment groups applies to all plots: Anti-GFP (10 mpk), R2M3 (10 mpk), R2M3-26 (1 mpk) + RSPO2 (0.3 mpk). (D-E) Histopathology assessment of the fibrosis score and the percentage lung fibrosis. (F) Percentage of the ACTA2 expression area to total tissue area. (G) Representative images showing ACTA2 expression for each treatment group; scale bar = 1 mm. Error bars represent SEM; * p value < 0.05, ** < 0.01, *** < 0.001